Casey Butrus, PharmD, leads a panel of experts in a discussion surrounding atopic dermatitis.

Key opinion leaders navigate diagnostic challenges associated with atopic dermatitis.

Dr Casey Butrus drives a discussion highlighting typical patient presentations of AD.

Brian Keegan, MD, PhD, and Michael Cameron, MD, FAAD, describe treatment options for patients with atopic dermatitis.

Medical experts navigate the selection process for optimal atopic dermatitis treatment strategies from provider and payer perspectives.

Managing itch associated with atopic dermatitis is a critical intervention to patient quality of life.

The panelists highlight the treatment nature of ruxolitinib, a JAK inhibitor used to treat atopic dermatitis.

Dr Butrus leads a discussion on the ideal patient population for treating atopic dermatitis with ruxolitinib.

Off-label use of JAK inhibitors can prove beneficial in the treatment of several dermatologic conditions.

Drs Keegan and Cameron discuss patient-specific considerations for selecting optimal atopic dermatitis treatment strategies.

White-glove service provided by local pharmacies can increase convenience for patients navigating atopic dermatitis (AD) treatment options.

Expert panelists discuss bridging communication between payers and providers in the AD treatment pathway.

Amy Brennan underlines the impact of affordability and how it may be inhibiting the patient atopic dermatitis (AD) treatment process.

In their final thoughts, medical experts highlight key considerations in the atopic dermatitis (AD) treatment landscape.